AbbVie Inc. $ABBV Shares Bought by Pacific Excel Wealth Advisors Inc.

Pacific Excel Wealth Advisors Inc. raised its holdings in AbbVie Inc. (NYSE:ABBV) by 150.6% in the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 5,697 shares of the company’s stock after buying an additional 3,424 shares during the quarter. Pacific Excel Wealth Advisors Inc.’s holdings in AbbVie were worth $1,434,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Litman Gregory Wealth Management LLC purchased a new position in shares of AbbVie in the 4th quarter valued at approximately $28,000. Imprint Wealth LLC grew its position in AbbVie by 56.2% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after purchasing an additional 45 shares during the last quarter. Legacy Wealth Managment LLC ID increased its stake in AbbVie by 115.9% during the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock valued at $31,000 after purchasing an additional 73 shares in the last quarter. IFC & Insurance Marketing Inc. acquired a new position in AbbVie during the 4th quarter valued at approximately $31,000. Finally, WestEnd Advisors LLC raised its holdings in shares of AbbVie by 160.4% in the fourth quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock worth $32,000 after buying an additional 85 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on ABBV shares. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a report on Monday, June 8th. Barclays raised their target price on AbbVie from $275.00 to $300.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Canaccord Genuity Group boosted their price target on AbbVie from $282.00 to $290.00 and gave the company a “buy” rating in a research note on Monday. Guggenheim increased their price objective on AbbVie from $261.00 to $288.00 and gave the company a “buy” rating in a report on Tuesday. Finally, JPMorgan Chase & Co. raised their price objective on AbbVie from $260.00 to $280.00 and gave the stock an “overweight” rating in a research note on Thursday, July 9th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $272.76.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: BOTOX Cosmetic expansion: The FDA accepted AbbVie’s supplemental application for BOTOX Cosmetic to treat masseter muscle prominence, commonly associated with a more prominent jawline. If approved, it would be the first U.S.-approved neurotoxin for this condition and would add a potential fifth aesthetic indication. The filing is supported by positive Phase 3 results. FDA acceptance of BOTOX Cosmetic application
• Positive Sentiment: Strong second-quarter performance: AbbVie reported revenue of $16.99 billion, up 10.2% year over year and above expectations, while adjusted earnings of $3.65 per share also exceeded consensus. Growth from immunology products Skyrizi and Rinvoq, along with neuroscience, is helping offset pressure from older products. AbbVie second-quarter results
• Positive Sentiment: UBRELVY reimbursement recommendation: Canada’s drug agency recommended conditional public reimbursement for UBRELVY in adults treating acute migraine. The recommendation could improve access and support international sales growth for AbbVie’s migraine franchise. UBRELVY Canadian reimbursement recommendation
• Positive Sentiment: Analyst optimism: Cantor Fitzgerald raised its AbbVie price target to $285 from $265 and maintained an Overweight rating, reflecting confidence in the company’s growth catalysts and pipeline.
• Neutral Sentiment: Pipeline and sector activity: AbbVie’s late-stage ABBV-706 lung-cancer program and telisotuzumab adizutecan remain potential longer-term catalysts, although neither update represents an immediate commercial milestone. Broader biopharmaceutical merger activity may also improve the sector’s sentiment. ABBV-706 lung cancer trial
• Negative Sentiment: Apogee acquisition impact: Although AbbVie raised its 2026 revenue outlook on Skyrizi, Rinvoq and neuroscience growth, the Apogee deal is expected to dilute earnings and increase research-and-development spending. This creates a near-term headwind despite stronger operating momentum.

AbbVie Price Performance

Shares of AbbVie stock opened at $243.83 on Wednesday. The firm has a fifty day moving average price of $240.29 and a 200 day moving average price of $224.41. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $267.47. The stock has a market cap of $430.80 billion, a PE ratio of 68.88, a price-to-earnings-growth ratio of 0.81 and a beta of 0.30.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 466.39%. The firm’s revenue was up 10.2% on a year-over-year basis. During the same period in the prior year, the company earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities analysts expect that AbbVie Inc. will post 14.08 EPS for the current year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be paid a $1.73 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.8%. AbbVie’s dividend payout ratio is presently 195.48%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.